BRICANYL
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Mar 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRICANYL is a small-molecule injectable medication approved by the FDA in 1974 for over 50 years of clinical use. The drug's specific mechanism of action and therapeutic indications are not detailed in available data, but its injectable formulation and long market presence suggest it addresses a sustained medical need. As a legacy NDA product, BRICANYL represents a mature, established therapeutic option in its class.
LOE Approaching
LOE approaching with moderate competitive pressure (30/100) suggests a shrinking commercial team focused on defense and cost management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3
Started Mar 2015
95 enrolled
Asthma
Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients
Started Sep 2009
66 enrolled
Exercise Induced Asthma
Career Relevance
With zero linked job openings and LOE approaching, BRICANYL represents a defensive career assignment focused on market protection and margin management rather than innovation or rapid growth. Career advancement opportunities are limited; roles emphasize operational efficiency, managed care negotiations, and customer retention in a declining revenue environment.
Worked on BRICANYL at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.